This was evidenced by delayed detection of the BRCA2 c.7934delG variant (initially in tumor DNA using NGS) in one of our study participants diagnosed with metachronous bladder cancer four years after receiving a low-risk MammaPrint result (44). The gene discussed is BRCA2; the disease is urinary bladder carcinoma.